))
The Logistics of Cell & Gene Therapy – From Benchmarking to Standardization (Part 2)
Manage episode 421185589 series 3554424
Content provided by Quick Group of Companies. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Quick Group of Companies or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In Part 2 of our conversation, Scott Ohanesian, QuickSTAT’s senior VP of Commercial Operations, and Mike Sweeney, QuickSTAT's Global Head of Strategy for CGT and Direct to Patient Products discuss the various challenges around the logistics of Cell & Gene Therapy – what to look out for and the importance of being prepared.
We also look forward and consider not only the sector’s growth, but what that growth will mean for supply chain logistics. To understand that future, however, we began by asking Mike Sweeney to provide the context of when gene therapy began – and, importantly, how we got from there to here?
For more information on clinical trial logistics, visit our website at quickstat.com.
4 episodes
Share
